MARKS AS MODIFIERS OF THE PTEN PATHWAY

AND METHODS OF USE

IC20 Rec'd PCT/PTO 1 0 NOV 2005

REFERENCE TO RELATED APPLICATIONS

5   This application claims priority to U.S. provisional patent application 60/479,768

filed 6/19/2003. The contents of the prior application are hereby incorporated in their

entirety.

BACKGROUND OF THE INVENTION

10   The AKT signaling pathway is frequently hyperactivated by a variety of

mechanisms in a wide range of human cancers, including melanoma, breast, lung, prostate,

and ovarian tumors (see Vivanco I and Sawyers CL (2002) Nat Rev Cancer. 2(7):489-501;

Scheid MPand Woodgett JR (2001) J Mammary Gland Biol Neoplasia. 6(1):83-99). In

tumor cells, the AKT protein kinase activity can be elevated by amplification and

15   overexpression of the AKT2 gene, or by increased production of phosphatidylinositol (3,

4, 5) trisphosphate (PIP$_3$), which activates AKT by recruitment to the plasma membrane.

In normal phosphoinositide metabolism, phosphatidylinositol (3, 4) bisphosphate (PIP$_2$) is

phosphorylated by phosphatidylinositol 3-kinase (PI3K) to generate PIP$_3$, and PIP$_3$ is

dephosphorylated back to PIP$_2$ by the lipid phosphatase PTEN. PIP$_3$ levels in tumors can

20   be enhanced by amplification and overexpression of PI3K, or by hyperactivation of the

PI3K activator IGF receptor. Most commonly, however, PIP$_3$ levels in tumor cells are

elevated by mutation or deletion of the PTEN tumor suppressor, at rates as high as 40-50%

of prostate cancers. The AKT pathway promotes tumor progression by enhancing cell

proliferation, growth, survival, and motility, and by suppressing apoptosis. These effects

25   are mediated by several AKT substrates, including the related transcription factors FKHR

and AFX, for which phosphorylation by AKT mediates nuclear export.

          All of the major AKT pathway components have structural and functional

orthologs in *C. elegans* that function in dauer larva formation (see Wolkow CA et al.

(2002) J Biol Chem 277(51):49591-7; Paradis S et al (1999) Genes Dev. 13(11):1438-52.).

30   Normally, environmental cues of low food (bacteria) levels, high dauer pheromone

concentration, and high temperature trigger a developmental decision that signals

alternative differentiation pathways in all tissues and entry into a diapause (dauer) arrest.

Inactivating mutations or RNAi of the AKT orthologs *akt-1* and *akt-2*, or the PI3K

ortholog *age-1*, or the IGF receptor *daf-2*, produce a dauer-constitutive (Daf-c) phenotype;

in which animals form dauers even under environmental conditions that normally induce
development to adulthood. Conversely, inactivating mutations in the PTEN ortholog *daf-
18*, or the FKHR and AFX ortholog *daf-16*, generate a dauer-defective (Daf-d) phenotype
and prevent dauer formation regardless of environmental conditions. A *daf-18* deletion
5   mutant fully suppresses the Daf-c phenotype of *age-1* and *daf-2* mutations (Gil EB et al
(1999) Proc Natl Acad Sci U S A. 96(6):2925-30.; Mihaylova VT et al (1999) Proc Natl
Acad Sci U S A. 96(13):7427-32), and we have identified two loss-of-function mutations
that allow non-dauer development of the heat-sensitive daf-2 (1370) allele at the non-
permissive temperature of 25°C. *daf-18 (ep496)* is a nonsense mutation at amino acid
10   E455, and *daf-18 (ep497)* is a missense mutation predicted to cause the amino acid
substitution G80D. The Daf-d phenotype of double mutants *daf-18 (ep496); daf-2 (e1370)*
and *daf-18 (ep497); and daf-2 (e1370)* can be reverted to a Daf-c phenotype by RNAi of
akt-1 or *age-1*, indicating that the double mutants display increased AKT signaling.

          Microtubules have a central role in the regulation of cell shape and polarity during
15   differentiation, chromosome partitioning at mitosis, and intracellular transport.
Microtubules undergo rearrangements involving rapid transitions between stable and
dynamic states during these processes. Microtubule affinity regulating kinases (MARK)
are a novel family of protein kinases that phosphorylate microtubule-associated proteins
and trigger microtubule disruption (Drewes, G., et al. (1997) Cell 89: 297-308).
20   Mammalian SNF1 like kinase (SNF1LK) is a serine/threonine kinase similar to Snf1
protein kinase of S. cerevisiae, which is involved in the response to nutritional stress.

          The ability to manipulate the genomes of model organisms such as *C. elegans*
provides a powerful means to analyze biochemical processes that, due to significant
evolutionary conservation, have direct relevance to more complex vertebrate organisms.
25   Due to a high level of gene and pathway conservation, the strong similarity of cellular
processes, and the functional conservation of genes between these model organisms and
mammals, identification of the involvement of novel genes in particular pathways and
their functions in such model organisms can directly contribute to the understanding of the
correlative pathways and methods of modulating them in mammals (see, for example,
30   Dulubova I, et al, J Neurochem 2001 Apr;77(1):229-38; Cai T, et al., Diabetologia 2001
Jan;44(1):81-8; Pasquinelli AE, et al., Nature. 2000 Nov 2;408(6808):37-8; Ivanov IP, et
al., EMBO J 2000 Apr 17;19(8):1907-17; Vajo Z et al., Mamm Genome 1999
Oct;10(10):1000-4). For example, a genetic screen can be carried out in an invertebrate
model organism having underexpression (e.g. knockout) or overexpression of a gene

(referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point. When

5   the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as PTEN, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in

10   their entireties.

SUMMARY OF THE INVENTION

We have discovered genes that modify the PTEN pathway in *C. elegans*, and identified their human orthologs, hereinafter referred to as Microtubule affinity regulating

15   kinases (MARK). The invention provides methods for utilizing these PTEN modifier genes and polypeptides to identify MARK-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired PTEN function and/or MARK function. Preferred MARK-modulating agents specifically bind to MARK polypeptides and restore PTEN function. Other preferred

20   MARK-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MARK gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

MARK modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with a MARK polypeptide or nucleic acid. In one

25   embodiment, candidate MARK modulating agents are tested with an assay system comprising a MARK polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate PTEN modulating agents. The assay system may be cell-based or cell-free. MARK-modulating agents include MARK related proteins (e.g. dominant negative mutants, and

30   biotherapeutics); MARK -specific antibodies; MARK -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MARK or compete with MARK binding partner (e.g. by binding to a MARK binding partner). In one specific embodiment, a small molecule modulator is identified using a kinase assay. In specific embodiments, the screening assay system is selected from a

binding assay, an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

In another embodiment, candidate PTEN pathway modulating agents are further tested using a second assay system that detects changes in the PTEN pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the PTEN pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

The invention further provides methods for modulating the MARK function and/or the PTEN pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a MARK polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated with the PTEN pathway.

DETAILED DESCRIPTION OF THE INVENTION

We designed a genetic screen to identify suppressor genes that, when inactivated, decrease signaling through the AKT pathway. The function of individual genes was inactivated by RNAi in the *daf-18 (ep496); daf-2 (e1370)* double mutant by soaking L1 larvae in double-stranded RNA for each gene. Methods for using RNAi to silence genes in *C. elegans* are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); WO9932619). Genes causing altered phenotypes in the worms were identified as modifiers of the PTEN pathway. The PAR-1 gene was identified as a modifier of the PTEN pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MARK genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective PTEN signaling pathway, such as cancer.

In vitro and in vivo methods of assessing MARK function are provided herein. Modulation of the MARK or their respective binding partners is useful for understanding the association of the PTEN pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for PTEN related pathologies. MARK-modulating agents that act by inhibiting or enhancing MARK expression, directly

or indirectly, for example, by affecting a MARK function such as enzymatic (e.g.,
catalytic) or binding activity, can be identified using methods provided herein. MARK
modulating agents are useful in diagnosis, therapy and pharmaceutical development.

5   Nucleic acids and polypeptides of the invention

        Sequences related to MARK nucleic acids and polypeptides that can be used in the
invention are disclosed in Genbank (referenced by Genbank identifier (GI) number) as
GI#s 17382968 (SEQ ID NO:1), 27597093 (SEQ ID NO:5), 23620491 (SEQ ID NO:6),
39812204 (SEQ ID NO:7), 13386467 (SEQ ID NO:8), 14133228 (SEQ ID NO:9),
10   30156409 (SEQ ID NO:10), 22064826 (SEQ ID NO:11), 30314571 (SEQ ID NO:12), and
38569459 (SEQ ID NO:13), for nucleic acid, and GI#s 9978891 (SEQ ID NO:14),
27597094 (SEQ ID NO:15), 14133229 (SEQ ID NO:16), 14770402 (SEQ ID NO:17), and
38569460 (SEQ ID NO:18) for polypeptide sequences. Additionally, nucleic acid
sequences of SEQ ID NOs:2, 3, and 4 can also be used in the invention.
15   The term "MARK polypeptide" refers to a full-length MARK protein or a
functionally active fragment or derivative thereof. A "functionally active" MARK
fragment or derivative exhibits one or more functional activities associated with a full-
length, wild-type MARK protein, such as antigenic or immunogenic activity, enzymatic
activity, ability to bind natural cellular substrates, etc. The functional activity of MARK
20   proteins, derivatives and fragments can be assayed by various methods known to one
skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John
Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one
embodiment, a functionally active MARK polypeptide is a MARK derivative capable of
rescuing defective endogenous MARK activity, such as in cell based or animal assays; the
25   rescuing derivative may be from the same or a different species. For purposes herein,
functionally active fragments also include those fragments that comprise one or more
structural domains of a MARK, such as a kinase domain or a binding domain. Protein
domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids
Res, 1999, 27:260-2). For example, the kinase domain (PFAM 00069) of MARK from
30   GI#s 27597094, 14133229, and 38569460 (SEQ ID NOs:15, 16, and 18, respectively) is
located respectively at approximately amino acid residues 27 to 278, 116 to 367, and 20 to
271. Methods for obtaining MARK polypeptides are also further described below. In
some embodiments, preferred fragments are functionally active, domain-containing
fragments comprising at least 25 contiguous amino acids, preferably at least 50, more

preferably 75, and most preferably at least 100 contiguous amino acids of a MARK. In further preferred embodiments, the fragment comprises the entire functionally active domain.

The term "MARK nucleic acid" refers to a DNA or RNA molecule that encodes a
5 MARK polypeptide. Preferably, the MARK polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MARK. Methods of identifying orthlogs are known in the art. Normally, orthologs in different
10 species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P,
15 Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA et al., Genome Research (2000) 10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse
20 species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species,
25 such as C. elegans, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term "orthologs" encompasses paralogs. As used herein, "percent (%) sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject
30 sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul et al., J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition

of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is

5   determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the

10   protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and

15   interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, Advances in Applied Mathematics 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, J. of Molec.Biol., 147:195-197; Nicholas et al., 1998, "A Tutorial on

20   Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, Genomics 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized

25   by Gribskov (Gribskov 1986 Nucl. Acids Res. 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

Derivative nucleic acid molecules of the subject nucleic acid molecules include

30   sequences that hybridize to the nucleic acid sequence of a MARK. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, Current Protocol in Molecular Biology, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook

et al., Molecular Cloning, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of a MARK under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of MARK Nucleic Acids and Polypeptides

MARK nucleic acids and polypeptides are useful for identifying and testing agents that modulate MARK function and for other applications related to the involvement of MARK in the PTEN pathway. MARK nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may

require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression

5   of a MARK protein for assays used to assess MARK function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (e.g., Higgins SJ and Hames BD (eds.) Protein Expression: A Practical Approach,

10 Oxford University Press Inc., New York 1999; Stanbury PF et al., Principles of Fermentation Technology, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) Protein Purification Protocols, Humana Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MARK is expressed in a cell line known to have defective

15 PTEN function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

The nucleotide sequence encoding a MARK polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MARK gene and/or its

20 flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the

25 expression of, modifies, and/or specifically processes the gene product may be used.

To detect expression of the MARK gene product, the expression vector can comprise a promoter operably linked to a MARK gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by

30 assaying for the expression of the MARK gene product based on the physical or functional properties of the MARK protein in *in vitro* assay systems (*e.g.* immunoassays).

The MARK protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection.

A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

5

Once a recombinant cell that expresses the MARK gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MARK proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

10

The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MARK or other genes associated with the PTEN pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

15

20 <u>Genetically modified animals</u>

Animal models that have been genetically modified to alter MARK expression may be used in *in vivo* assays to test for activity of a candidate PTEN modulating agent, or to further assess the role of MARK in a PTEN pathway process such as apoptosis or cell proliferation. Preferably, the altered MARK expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MARK expression. The genetically modified animal may additionally have altered PTEN expression (e.g. PTEN knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into

25

30

the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos.

5   4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford et al.; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. et

10   al., A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S., Transgenic Zebrafish, Methods Mol Biol. (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for transgenic rats see Hammer et al., Cell (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent

15   production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. et al. (1997) Nature 385:810-813; and PCT

20   International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous MARK gene that results in a decrease of MARK function, preferably such that MARK expression is undetectable or insignificant. Knock-out animals are typically generated by homologous

25   recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MARK gene is used to construct a

30   homologous recombination vector suitable for altering an endogenous MARK gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, Science (1989) 244:1288-1292; Joyner et al., Nature (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel et al., Science (1989)

244:1281-1288; Simms *et al.*, Bio/Technology (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH et al., (1994) Scan J Immunol 40:257-264; Declerck PJ et

5   al., (1995) J Biol Chem. 270:8397-400).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MARK gene, e.g., by introduction of additional copies of MARK, or by operatively inserting a regulatory sequence that provides for

10   altered expression of an endogenous copy of the MARK gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that

15   may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two

20   transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the

25   transgene, and for sequential deletion of vector sequences in the same cell (Sun X et al (2000) Nat Genet 25:83-6).

The genetically modified animals can be used in genetic studies to further elucidate the PTEN pathway, as animal models of disease and disorders implicating defective PTEN function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in

30   screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MARK function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MARK expression that receive candidate therapeutic agent.

In addition to the above-described genetically modified animals having altered MARK function, animal models having defective PTEN function (and otherwise normal MARK function), can be used in the methods of the present invention. For example, a mouse with defective DAF18 function can be used to assess, *in vivo*, the activity of a

5   candidate DAF18 modulating agent identified in one of the *in vitro* assays described below. Transgenic mice with defective DAF18/PTEN function have been described in literature (DiCristofano A et al (1998) Nat genet 19:348-355). Preferably, the candidate PTEN modulating agent when administered to a model system with cells defective in PTEN function, produces a detectable phenotypic change in the model system indicating

10   that the PTEN function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

The invention provides methods to identify agents that interact with and/or modulate the function of MARK and/or the PTEN pathway. Modulating agents identified

15   by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the PTEN pathway, as well as in further analysis of the MARK protein and its contribution to the PTEN pathway. Accordingly, the invention also provides methods for modulating the PTEN pathway comprising the step of specifically modulating MARK activity by administering a MARK-

20   interacting or -modulating agent.

As used herein, an "MARK-modulating agent" is any agent that modulates MARK function, for example, an agent that interacts with MARK to inhibit or enhance MARK activity or otherwise affect normal MARK function. MARK function can be affected at any level, including transcription, protein expression, protein localization, and cellular or

25   extra-cellular activity. In a preferred embodiment, the MARK - modulating agent specifically modulates the function of the MARK. The phrases "specific modulating agent", "specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the MARK polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MARK. These phrases also encompass modulating

30   agents that alter the interaction of the MARK with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of a MARK, or to a protein/binding partner complex, and altering MARK function). In a further preferred embodiment, the MARK-modulating agent is a modulator of the PTEN pathway (e.g. it restores and/or upregulates PTEN function) and-thus is also a PTEN-modulating agent.

Preferred MARK-modulating agents include small molecule compounds; MARK-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may

5   comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

10   **Small molecule modulators**

Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more

15   preferably up to 1,000, and most preferably up to 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MARK protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products,

20   particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MARK-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

Small molecule modulators identified from screening assays, as described below,

25   can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the PTEN pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate

30   modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

Specific MARK-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the PTEN pathway and related disorders, as well as in validation assays for other MARK-modulating agents. In a preferred embodiment,

5   MARK-interacting proteins affect normal MARK function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MARK-interacting proteins are useful in detecting and providing information about the function of MARK proteins, as is relevant to PTEN related disorders, such as cancer (e.g., for diagnostic means).

10   An MARK-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with a MARK, such as a member of the MARK pathway that modulates MARK expression, localization, and/or activity. MARK-modulators include dominant negative forms of MARK-interacting proteins and of MARK proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying

15   endogenous MARK-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative

20   preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

An MARK-interacting protein may be an exogenous protein, such as a MARK-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane

25   (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MARK antibodies are further discussed below.

In preferred embodiments, a MARK-interacting protein specifically binds a MARK protein. In alternative preferred embodiments, a MARK-modulating agent binds a MARK substrate, binding partner, or cofactor.

30

Antibodies

In another embodiment, the protein modulator is a MARK specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MARK modulators. The antibodies can also be used

in dissecting the portions of the MARK pathway responsible for various cellular responses and in the general processing and maturation of the MARK.

Antibodies that specifically bind MARK polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MARK

5   polypeptide, and more preferably, to human MARK. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MARK which are particularly antigenic can be selected, for example, by

10   routine screening of MARK polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Nati. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of a MARK. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1}, or

15   stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MARK or substantially purified fragments thereof. If MARK fragments are used, they preferably comprise at least 10, and more preferably, at

20   least 20 contiguous amino acids of a MARK protein. In a particular embodiment, MARK-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system

25   such as a laboratory rabbit or mouse is immunized according to conventional protocols.

The presence of MARK-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MARK polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

30   Chimeric antibodies specific to MARK polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing

together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions

5   (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS,

10 and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

MARK-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via

15 an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of

20 antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, supra).

The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently

25 or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent

30 emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may

be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The

5   therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently

10 nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in

15 such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Nucleic Acid Modulators

20   Other preferred MARK-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MARK activity. Preferred nucleic acid modulators interfere with the function of the MARK nucleic acid such as DNA replication, transcription, translocation of the MARK RNA to the site of protein translation, translation of protein from the MARK RNA, splicing of the

25 MARK RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MARK RNA.

In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to a MARK mRNA to bind to and prevent translation, preferably by binding to the 5′ untranslated region. MARK-specific antisense oligonucleotides,

30 preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be

modified at the base moiety, sugar moiety, or phosphate backbone... The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

5   In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiamidate intersubunit linkages. Details of how to make and use PMOs and other antisense

10   oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

        Alternative preferred MARK nucleic acid modulators are double-stranded RNA

15   species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363

20   (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200

25   (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

        Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used,

30   for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al*, Current Concepts in Antisense Drug Design, J Med-Chem. (1993) 36:1923-1937; Tonkinson JL *et al.*, Antisense

Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65).
Accordingly, in one aspect of the invention, a MARK-specific nucleic acid modulator is
used in an assay to further elucidate the role of the MARK in the PTEN pathway, and/or
its relationship to other members of the pathway. In another aspect of the invention, a
5   MARK-specific antisense oligomer is used as a therapeutic agent for treatment of PTEN-
related disease states.

Assay Systems
        The invention provides assay systems and screening methods for identifying
10   specific modulators of MARK activity. As used herein, an "assay system" encompasses
all the components required for performing and analyzing results of an assay that detects
and/or measures a particular event. In general, primary assays are used to identify or
confirm a modulator's specific biochemical or molecular effect with respect to the MARK
nucleic acid or protein. In general, secondary assays further assess the activity of a
15   MARK modulating agent identified by a primary assay and may confirm that the
modulating agent affects MARK in a manner relevant to the PTEN pathway. In some
cases, MARK modulators will be directly tested in a secondary assay.
        In a preferred embodiment, the screening method comprises contacting a suitable
assay system comprising a MARK polypeptide or nucleic acid with a candidate agent
20   under conditions whereby, but for the presence of the agent, the system provides a
reference activity (e.g. kinase activity), which is based on the particular molecular event
the screening method detects. A statistically significant difference between the agent-
biased activity and the reference activity indicates that the candidate agent modulates
MARK activity, and hence the PTEN pathway. The MARK polypeptide or nucleic acid
25   used in the assay may comprise any of the nucleic acids or polypeptides described above.

        Primary Assays
        The type of modulator tested generally determines the type of primary assay.

30   *Primary assays for small molecule modulators*
        For small molecule modulators, screening assays are used to identify candidate
modulators. Screening assays may be cell-based or may use a cell-free system that
recreates or retains the relevant biochemical reaction of the target protein (reviewed in
Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying

references)...As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude

5　cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (e.g., receptor-ligand binding), transcriptional activity (e.g., using a reporter gene), enzymatic activity (e.g., via a property of the substrate), activity of second messengers, immunogenicty and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide

10　range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

　　Cell-based screening assays usually require systems for recombinant expression of MARK and any auxiliary proteins demanded by the particular assay. Appropriate

15　methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MARK-interacting

20　proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MARK protein may be assayed by various known methods such as substrate processing (e.g. ability of the candidate MARK-specific binding agents to function as negative effectors in MARK-expressing cells), binding equilibrium constants (usually at least about $10^7\,M^{-1}$, preferably at least about $10^8\,M^{-1}$, more preferably

25　at least about $10^9\,M^{-1}$), and immunogenicity (e.g. ability to elicit MARK specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

　　The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MARK polypeptide, a fusion protein thereof, or to cells or

30　membranes bearing the polypeptide or fusion protein. The MARK polypeptide can be full length or a fragment thereof that retains functional MARK activity. The MARK polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MARK polypeptide is preferably human MARK, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the

screening assay detects candidate agent-based modulation of MARK interaction with a

binding target, such as an endogenous or exogenous protein or other substrate that has

MARK –specific binding activity, and can be used to assess normal MARK gene function.

     Suitable assay formats that may be adapted to screen for MARK modulators are

5   known in the art. Preferred screening assays are high throughput or ultra high throughput

and thus provide automated, cost-effective means of screening compound libraries for lead

compounds (Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Sundberg SA, Curr

Opin Biotechnol 2000, 11:47-53). In one preferred embodiment, screening assays uses

fluorescence technologies, including fluorescence polarization, time-resolved

10   fluorescence, and fluorescence resonance energy transfer. These systems offer means to

monitor protein-protein or DNA-protein interactions in which the intensity of the signal

emitted from dye-labeled molecules depends upon their interactions with partner

molecules (*e.g.*, Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, *supra*;

Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451).

15   A variety of suitable assay systems may be used to identify candidate MARK and

PTEN pathway modulators (e.g. U.S. Pat. No. 6,165,992 (kinase assays); U.S. Pat, Nos.

5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and

6,444,434 (angiogenesis assays), among others). Specific preferred assays are described

in more detail below.

20

     Kinase assays. In some preferred embodiments the screening assay detects the

ability of the test agent to modulate the kinase activity of a MARK polypeptide. In further

embodiments, a cell-free kinase assay system is used to identify a candidate PTEN

modulating agent, and a secondary, cell-based assay, such as an apoptosis or hypoxic

25   induction assay (described below), may be used to further characterize the candidate

PTEN modulating agent. Many different assays for kinases have been reported in the

literature and are well known to those skilled in the art (e.g. U.S. Pat. No. 6,165,992; Zhu

et al., Nature Genetics (2000) 26:283-289; and WO0073469). Radioassays, which

monitor the transfer of a gamma phosphate are frequently used. For instance, a

30   scintillation assay for p56 (lck) kinase activity monitors the transfer of the gamma

phosphate from gamma -^{33}P ATP to a biotinylated peptide substrate; the substrate is

captured on a streptavidin coated bead that transmits the signal (Beveridge M *et al.*, J

Biomol Screen (2000) 5:205-212). This assay uses the scintillation proximity assay

(SPA), in which only radio-ligand bound to receptors tethered to the surface of an SPA

bead are detected by the scintillant immobilized within it, allowing binding to be measured without separation of bound from free ligand.

     Other assays for protein kinase activity may use antibodies that specifically recognize phosphorylated substrates. For instance, the kinase receptor activation (KIRA)
5   assay measures receptor tyrosine kinase activity by ligand stimulating the intact receptor in cultured cells, then capturing solubilized receptor with specific antibodies and quantifying phosphorylation via phosphotyrosine ELISA (Sadick MD, Dev Biol Stand (1999) 97:121-133).

     Another example of antibody based assays for protein kinase activity is TRF (time-
10 resolved fluorometry). This method utilizes europium chelate-labeled anti-phosphotyrosine antibodies to detect phosphate transfer to a polymeric substrate coated onto microtiter plate wells. The amount of phosphorylation is then detected using time-resolved, dissociation-enhanced fluorescence (Braunwalder AF, et al., Anal Biochem 1996 Jul 1;238(2):159-64).

15

     Apoptosis assays. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik et al., 1994, Nature 371, 346), by following the incorporation of
20 fluorescein-dUTP (Yonehara et al., 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell
25 death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE[TM] Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat#
30 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane

breaks down, allowing for accumalation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. An apoptosis assay system may comprise a cell that expresses a MARK, and that optionally has defective PTEN function (e.g. PTEN is over-expressed or under-expressed relative to wild-type

5   cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate PTEN modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate PTEN modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test

10   whether MARK function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MARK relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MARK plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

15

      Cell proliferation and cell cycle assays. Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et*

20   *al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by other means.

      Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specfic to the phosphorylated form

25   of the serine 10 residue of histone H3. (Chadlee,D.N. 1995, J. Biol. Chem 270:20098-105). Cell Proliferation may also be examined using [^{3}H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [^{3}H]-thymidine into newly synthesized DNA.

30   Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL et al., 1998, In Vitro Cell Dev

Biol Anim 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96$^{®}$ AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

5   Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). For example, cells transformed with MARK are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

Cell proliferation may also be assayed by measuring ATP levels as indicator of
10   metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo™, which is a luminescent homogeneous assay available from Promega.

Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) Int J Radiat Biol Relat Stud Phys Chem Med 49:237-55). Cells transfected with a MARK may be stained with propidium iodide and evaluated in a flow
15   cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.

Involvement of a gene in cell cycle may also be assayed by FOXO nuclear translocation assays. The FOXO family of transcription factors are mediators of various cellular functions including cell cycle progression and cell death, and are negatively
20   regulated by activation of the PI3 kinase pathway. Akt phosphorylation of FOXO family members leads to FOXO sequestration in the cytoplasm and transcriptional inactivation (Medema, R. H et al (2000) Nature 404: 782-787). PTEN is a negative regulator of PI3 kinase pathway. Activation of PTEN, or loss of PI3 kinase or AKT, prevents phosphorylation of FOXO, leading to accumulation of FOXO in the nucleus,
25   transcriptional activation of FOXO regulated genes, and apoptosis. Alternatively, loss of PTEN leads to pathway activation and cell survival (Nakamura, N. et al (2000) Mol Cell Biol 20: 8969-8982). FOXO translocation into the cytoplasm is used in assays and screens to identify members and/or modulators of the PTEN pathway. FOXO translocation assays using GFP or luciferase as detection reagents are known in the art (e.g., Zhang X et al
30   (2002) J Biol Chem 277:45276-45284; and Li et al (2003) Mol Cell Biol 23:104-118).

Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses a MARK, and that optionally has defective PTEN function (e.g. PTEN is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where

no test agent is added, identify candidate PTEN modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate PTEN modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test

5   whether MARK function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MARK relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MARK plays a direct role in cell proliferation or cell cycle.

10

Angiogenesis. Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton

15   Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a MARK, and that optionally has defective PTEN function

20   (e.g. PTEN is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate PTEN modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate PTEN modulating agents that is initially identified using another

25   assay system. An angiogenesis assay may also be used to test whether MARK function plays a direct role in cell proliferation. For example, an angiogenesis assay may be performed on cells that over- or under-express MARK relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MARK plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among

30   others, describe various angiogenesis assays.

Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be

important in tumour cell survival, such as those encoding glyolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MARK in hypoxic conditions (such as with 0.1% O2, 5% CO2, and balance N2, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic

5 conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses a MARK, and that optionally has defective PTEN function (e.g. PTEN is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is

10 added, identify candidate PTEN modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate PTEN modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MARK function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed

15 on cells that over- or under-express MARK relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MARK plays a direct role in hypoxic induction.

Cell adhesion. Cell adhesion assays measure adhesion of cells to purified

20 adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked

25 with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

30 Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as

BCECF , and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. In one such assay,
5   small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et
10   al., Bioconjug Chem. 2001 May-Jun;12(3):346-53).

Tubulogenesis. Tubulogenesis assays monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix. Exemplary substrates
15   include Matrigel™ (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4°C and forms a solid gel at 37°C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally
20   be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art (e.g., Jones MK et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. Serum represents an undefined source of growth factors. In a preferred embodiment, the assay is performed
25   with cells cultured in serum free medium, in order to control which process or pathway a candidate agent modulates. Moreover, we have found that different target genes respond differently to stimulation with different pro-angiogenic agents, including inflammatory angiogenic factors such as TNF-alpa. Thus, in a further preferred embodiment, a tubulogenesis assay system comprises testing a MARK's response to a variety of factors,
30   such as FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

Cell Migration. An invasion/migration assay (also called a migration assay) tests the ability of cells to overcome a physical barrier and to migrate towards pro-angiogenic signals. Migration assays are known in the art (e.g., Paik JH et al., 2001, J Biol Chem

28

276:11830-11837). In a typical experimental set-up, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The matrix generally simulates the environment of the extracellular matrix, as described above. The lamina is typically a membrane, such as the transwell polycarbonate

5   membrane (Corning Costar Corporation, Cambridge, MA), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin

10   solution (VWR Scientific, South San Francisco, CA), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FluoroBlok (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to pro-angiogenic factors. As

15   described above, a preferred assay system for migration/invasion assays comprises testing a MARK's response to a variety of pro-angiogenic factors, including tumor angiogenic and inflammatory angiogenic agents, and culturing the cells in serum free medium.

        Sprouting assay. A sprouting assay is a three-dimensional *in vitro* angiogenesis

20   assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58). In an

25   exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341-52, 1998). Spheroids are harvested and seeded in $900\mu l$ of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents

30   are added after 30 min by pipetting 100 μl of 10-fold concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

Primary assays for antibody modulators

For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MARK protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999,

5   *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting MARK-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

10

Primary assays for nucleic acid modulators

For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MARK gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MARK expression in like populations

15   of cells (*e.g.*, two pools of cells that endogenously or recombinantly express MARK) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MARK mRNA

20   expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, *eds.*, John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly

25   detected with specific antibodies or antisera directed against either the MARK protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MARK mRNA expression, may also be used to

30   test nucleic acid modulators.

Secondary Assays

Secondary assays may be used to further assess the activity of MARK-modulating agent identified by any of the above methods to confirm that the modulating agent affects

30

MARK in a manner relevant to the PTEN pathway. As used herein, MARK-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity

5   of the modulating agent's interaction with MARK.

Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express MARK) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MARK–modulating agent results in changes

10   in the PTEN pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use "sensitized genetic backgrounds", which, as used herein, describe cells or animals engineered for altered expression of genes in the PTEN or interacting pathways.

15   *Cell-based assays*

Cell based assays may detect endogenous PTEN pathway activity or may rely on recombinant expression of PTEN pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious

20   means.

Animal Assays

A variety of non-human animal models of normal or defective PTEN pathway may be used to test candidate MARK modulators. Models for defective PTEN pathway

25   typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the PTEN pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

In a preferred embodiment, PTEN pathway activity is assessed by monitoring

30   neovascularization and angiogenesis. Animal models with defective and normal PTEN are used to test the candidate modulator's affect on MARK in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various

angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MARK. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous

5   (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

In another preferred embodiment, the effect of the candidate modulator on MARK

10   is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, e.g., Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MARK endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of

15   100 μL using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed

20   by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly

25   frozen in isopentane cooled with liquid nitrogen.

In another preferred embodiment, tumorogenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent,

30   and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorogenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can

be determined by tests known in the art, for example, MTT dye conversion assay, neutral

red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in

soft agar, the capacity of the cells to recover and replicate in vitro, etc.

In another preferred embodiment, a tumorigenicity assay use a transgenic animal,

5   usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under

the control of tissue specific regulatory sequences; these assays are generally referred to as

transgenic tumor assays. In a preferred application, tumor development in the transgenic

model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2"

transgene, comprising the SV40 large T-antigen oncogene under control of the insulin

10   gene regulatory regions is expressed in pancreatic beta cells and results in islet cell

carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad

Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic

switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset

of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14

15   weeks. Candidate modulators may be administered at a variety of stages, including just

prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of

small tumors (e.g., for a model of intervention), or during the growth of large and/or

invasive tumors (e.g., for a model of regression). Tumorogenicity and modulator efficacy

can be evaluating life-span extension and/or tumor characteristics, including number of

20   tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

Specific MARK-modulating agents are useful in a variety of diagnostic and

therapeutic applications where disease or disease prognosis is related to defects in the

25   PTEN pathway, such as angiogenic, apoptotic, or cell proliferation disorders.

Accordingly, the invention also provides methods for modulating the PTEN pathway in a

cell, preferably a cell pre-determined to have defective or impaired PTEN function (e.g.

due to overexpression, underexpression, or misexpression of PTEN, or due to gene

mutations), comprising the step of administering an agent to the cell that specifically

30   modulates MARK activity. Preferably, the modulating agent produces a detectable

phenotypic change in the cell indicating that the PTEN function is restored. The phrase

"function is restored", and equivalents, as used herein, means that the desired phenotype is

achieved, or is brought closer to normal compared to untreated cells. For example, with

restored PTEN function, cell proliferation and/or progression through cell cycle may

normalize, or be brought closer to normal relative to untreated cells.   The invention also

provides methods for treating disorders or disease associated with impaired PTEN

function by administering a therapeutically effective amount of a MARK -modulating

agent that modulates the PTEN pathway. The invention further provides methods for

5   modulating MARK function in a cell, preferably a cell pre-determined to have defective or

impaired MARK function, by administering a MARK -modulating agent. Additionally,

the invention provides a method for treating disorders or disease associated with impaired

MARK function by administering a therapeutically effective amount of a MARK -

modulating agent.

10   The discovery that MARK is implicated in PTEN pathway provides for a variety of

methods that can be employed for the diagnostic and prognostic evaluation of diseases and

disorders involving defects in the PTEN pathway and for the identification of subjects

having a predisposition to such diseases and disorders.

              Various expression analysis methods can be used to diagnose whether MARK

15   expression occurs in a particular sample, including Northern blotting, slot blotting,

ribonuclease protection, quantitative RT-PCR, and microarray analysis. (*e.g.*, Current

Protocols in Molecular Biology (1994) Ausubel FM *et al.*, *eds.*, John Wiley & Sons, Inc.,

chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann

Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47).

20   Tissues having a disease or disorder implicating defective PTEN signaling that express a

MARK, are identified as amenable to treatment with a MARK modulating agent. In a

preferred application, the PTEN defective tissue overexpresses a MARK relative to

normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal

cell lines, or from tumor and matching normal tissue samples from the same patient, using

25   full or partial MARK cDNA sequences as probes, can determine whether particular tumors

express or overexpress MARK. Alternatively, the TaqMan® is used for quantitative RT-

PCR analysis of MARK expression in cell lines, normal tissues and tumor samples (PE

Applied Biosystems).

              Various other diagnostic methods may be performed, for example, utilizing

30   reagents such as the MARK oligonucleotides, and antibodies directed against a MARK, as

described above for: (1) the detection of the presence of MARK gene mutations, or the

detection of either over- or under-expression of MARK mRNA relative to the non-

disorder state; (2) the detection of either an over- or an under-abundance of MARK gene

product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MARK.

      Kits for detecting expression of MARK in various samples, comprising at least one antibody specific to MARK, all reagents and/or devices suitable for the detection of

5   antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided.

      Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MARK expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting

10   the sample with a probe for MARK expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 1. The probe may be either DNA or protein, including an antibody.

15   **EXAMPLES**

      The following experimental section and examples are offered by way of illustration and not by way of limitation.

      I.   C. elegans PTEN screen

20   We designed a genetic screen to identify suppressor genes that, when inactivated, decrease signaling through the AKT pathway. The function of individual genes was inactivated by RNAi in the *daf-18 (ep496); daf-2 (e1370)* double mutant by soaking L1 larvae in double-stranded RNA for each gene. Subsequently, the larvae were grown on bacteria at 25°C and scored for a statistically significant increase in dauer formation as

25   compared to larvae treated without RNA (approximately 0-2% dauers). Suppressor genes were counter-screened to eliminate those that showed allele-specific suppression of the *ep496* nonsense mutation but not the *ep497* missense mutation by performing RNAi on the *daf-18 (ep497); daf-2 (e1370)* double mutant and scoring for enhanced dauer formation at 25°C. *daf-16* mutations provide a test for pathway specificity since they fully suppress the

30   Daf-c phenotype of all known AKT pathway mutants but, at most, only weakly suppress the Daf-c phenotype of mutants in the *daf-7* (TGF-□) and *daf-11* (cGMP signaling) pathways. Therefore, we also counter-screened suppressor genes to eliminate those that increased dauer formation in a *daf-18 (ep496); daf-1 (e1370); daf-16 (mgDf47)* triple

mutant. PAR-1 was an identified modifier. Orthologs of the modifiers are referred to herein as MARK.

BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of C.elegans modifiers. For example, representative sequences from MARK, GIs#

5   27597094, 14133229, and 38569460 (SEQ ID NOs:15, 16, and 18, respectively) share 52%, 51%, and 54% amino acid identity, respectively, with the *C.elegans* PAR-1.

Various domains, signals, and functional subunits in proteins were analyzed using the PSORT (Nakai K., and Horton P., Trends Biochem Sci, 1999, 24:34-6; Kenta Nakai, Protein sorting signals and prediction of subcellular localization, Adv. Protein Chem. 54,

10   277-344 (2000)), PFAM (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2), SMART (Ponting CP, et al., SMART: identification and annotation of domains from signaling and extracellular protein sequences. Nucleic Acids Res. 1999 Jan 1;27(1):229-32), TM-HMM (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of

15   Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998), and clust (Remm M, and Sonnhammer E.   Classification of transmembrane protein families in the Caenorhabditis elegans genome and identification of human orthologs. Genome Res. 2000 Nov;10(11):1679-89) programs. For example, the kinase

20   domain (PFAM 00069) of MARK from GI#s 27597094, 14133229, and 38569460 (SEQ ID NOs:15, 16, and 18, respectively) is located respectively at approximately amino acid residues 27 to 278, 116 to 367, and 20 to 271.

II.   High-Throughput In Vitro Fluorescence Polarization Assay

25   Fluorescently-labeled MARK peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate

30   modifier of MARK activity.

III.   High-Throughput In Vitro Binding Assay.

^{33}P-labeled MARK peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl$_2$, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1

mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a

Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated

substrate is then added to each well and incubated for 1 hour. Reactions are stopped by

washing with PBS, and counted in a scintillation counter. Test agents that cause a

5   difference in activity relative to control without test agent are identified as candidate

PTEN modulating agents.

IV.   Immunoprecipitations and Immunoblotting

For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells

10   containing the MARK proteins are plated on 10-cm dishes and transfected on the

following day with expression constructs. The total amount of DNA is kept constant in

each transfection by adding empty vector. After 24 h, cells are collected, washed once

with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer

containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM

15   sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease

inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular

debris is removed by centrifugation twice at $15,000 \times g$ for 15 min. The cell lysate is

incubated with 25 μl of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

After extensive washing with lysis buffer, proteins bound to the beads are

20   solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel

electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the

indicated antibodies. The reactive bands are visualized with horseradish peroxidase

coupled to the appropriate secondary antibodies and the enhanced chemiluminescence

(ECL) Western blotting detection system (Amersham Pharmacia Biotech).

25

V.   Kinase assay

A purified or partially purified MARK is diluted in a suitable reaction buffer, e.g.,

50 mM Hepes, pH 7.5, containing magnesium chloride or manganese chloride (1-20 mM)

and a peptide or polypeptide substrate, such as myelin basic protein or casein (1-10

30   μg/ml). The final concentration of the kinase is 1-20 nM. The enzyme reaction is

conducted in microtiter plates to facilitate optimization of reaction conditions by

increasing assay throughput. A 96-well microtiter plate is employed using a final volume

30-100 μl. The reaction is initiated by the addition of ^{33}P-gamma-ATP (0.5 μCi/ml) and

incubated for 0.5 to 3 hours at room temperature. Negative controls are provided by the

addition of EDTA, which chelates the divalent cation ($Mg2^+$ or Mn^{2+}) required for
enzymatic activity. Following the incubation, the enzyme reaction is quenched using
EDTA. Samples of the reaction are transferred to a 96-well glass fiber filter plate
(MultiScreen, Millipore). The filters are subsequently washed with phosphate-buffered

5   saline, dilute phosphoric acid (0.5%) or other suitable medium to remove excess
radiolabeled ATP. Scintillation cocktail is added to the filter plate and the incorporated
radioactivity is quantitated by scintillation counting (Wallac/Perkin Elmer). Activity is
defined by the amount of radioactivity detected following subtraction of the negative
control reaction value (EDTA quench).

10

VI.   Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute)
lines, and are available from ATCC (American Type Culture Collection, Manassas, VA
20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech,

15   Stratagene, Ardais, Genome Collaborative, and Ambion.

TaqMan® analysis was used to assess expression levels of the disclosed genes in
various samples.

RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy
kits, following manufacturer's protocols, to a final concentration of 50ng/µl. Single

20   stranded cDNA was then synthesized by reverse transcribing the RNA samples using
random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of
Applied Biosystems (Foster City, CA).

Primers for expression analysis using TaqMan® assay (Applied Biosystems,
Foster City, CA) were prepared according to the TaqMan® protocols, and the following

25   criteria: a) primer pairs were designed to span introns to eliminate genomic contamination,
and b) each primer pair produced only one product. Expression analysis was performed
using a 7900HT instrument.

TaqMan® reactions were carried out following manufacturer's protocols, in 25 µl
total volume for 96-well plates and 10 µl total volume for 384-well plates, using 300nM

30   primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for
result analysis was prepared using a universal pool of human cDNA samples, which is a
mixture of cDNAs from a wide variety of tissues so that the chance that a target will be
present in appreciable amounts is good. The raw data were normalized using 18S rRNA
(universally expressed in all tissues and cells).

For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., Tumor – average(all normal samples) > 2 x STDEV(all normal samples)).

Results are shown in Table 1. Number of pairs of tumor samples and matched normal tissue from the same patient are shown for each tumor type. Percentage of the samples with at least two-fold overexpression for each tumor type is provided. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Table 1

SEQ ID NO	8	5
Breast	8%	22%
# of Pairs	36	36
Colon	5%	21%
# of Pairs	41	38
Head And Neck	0%	23%
# of Pairs	13	13
Kidney	5%	10%
# of Pairs	22	20
Liver	11%	25%
# of Pairs	9	8
Lung	0%	13%
# of Pairs	42	38
Lymphoma	0%	0%
# of Pairs	4	4

Ovary	0%	16%
# of Pairs	19	19
Pancreas	58%	31%
# of Pairs	12	13
Prostate	8%	4%
# of Pairs	24	24
Skin	14%	14%
# of Pairs	7	7
Stomach	0%	0%
# of Pairs	11	11
Testis	0%	0%
# of Pairs	8	8
Thyroid Gland	0%	29%
# of Pairs	14	14
Uterus	0%	4%
# of Pairs	23	23

VII.   MARK functional assays

RNAi experiments were carried out to knock down expression of MARK

sequences (SEQ ID NOs:5, 8, and 10) in various cell lines using small interfering RNAs

5   (siRNA, Elbashir et al, *supra*).

Effect of MARK RNAi on cell proliferation and growth. BrdU and Cell Titer-

Glo™ assays, as described above, were employed to study the effects of decreased MARK

expression on cell proliferation. The results of these experiments indicated that RNAi of

SEQ ID NO:5 decreased proliferation in 231T breast cancer and HCT116 colon cancer

10   cells; RNAi of SEQ ID NO:8 and SEQ ID NO:10 decreased proliferation in 231T breast

cancer, PC3 prostate cancer, and HCT116 colon cancer cells. MTS and [^{3}H]-thymidine

incorporation cell proliferation assays, as described above, were also employed to study

the effects of decreased MARK expression on cell proliferation. The results of these

experiment indicated that RNAi of SEQ ID NOs:5 and 8 decreased proliferation in PC3

15   prostate cancer cells, A549 lung cancer, and RD1 rhabdomyosarcoma cells in both assays.

RNAi of SEQ ID NO:10 decreased proliferation in PC3 prostate cancer cells, A549 lung

cancer, and RD1 rhabdomyosarcoma cells in the MTS assay, and PC3 prostate cancer cells

and A549 lung cancer cells in the [^{3}H]-thymidine assay. Standard colony growth assays,

as described above, were employed to study the effects of decreased MARK expression on

20   cell growth. Decerased expression of SEQ ID NO:5 led to decreased cell growth in PC3

prostate cancer cells, SW480 colon cancer cells, and RD1 rhabdomyosarcoma cells;

decreased expression of SEQ ID NOs:8 and 10 each led to decreased cell growth in A549

lung cancer cells, PC3 prostate cancer cells, SW480 colon cancer cells, and RD1 rhabdomyosarcoma cells.

Effect of MARK RNAi on apoptosis. Nucleosome ELISA apoptosis assay, as described above, was employed to study the effects of decreased MARK expression on 5 apoptosis. Decreased expression of SEQ ID NO:5, 8, and 10 each led to apoptosis in A549 lung cancer cells.

MARK overexpression analysis. MARK (SEQ ID NO:5) was overexpressed in MDCK cells and tested in colony growth assays as described above. Overexpressed SEQ ID NO:5 had morphological effects on cells, and moderate effects on colony growth. 10 Further, when transfected along with RAS in NIH3T3 cells, SEQ ID NO:5 caused transformation of the cells, as compared with vector alone, RAS alone, or SEQ ID NO:5 alone. Effects of overexpressed MARK on expression of various transcription factors was also studied. Overexpressed SEQ ID NO:5 caused an increased expression of the EGR (Early growth response) and SRE (Serum response element).

15 MARK FOXO nuclear translocation assays. FOXO nuclear translocation assays, as described above, were employed to assess involvement of MARK in the PTEN/IGF pathway. In these experiments, cells with reduced expression of MARK by RNAi were transiently transfected with a plasmid expressing GFP-tagged FOXO. Automated imaging of cellular components, such as nucleus and cytoplasm were then carried out to assess 20 translocation of FOXO. Results indicated that reduced expression of SEQ ID NO:5, 8, and 10 each led to retention of FOXO in the nucleus, similar to a reduced AKT effect in PC3 prostate cancer cells. In another set of experiments, cells were co-transfected with siRNA directed to MARK along with a plasmid containing FOXO, and a cassette containing a promoter, a FOXO response element, and luciferase. Cells were then 25 analyzed for luciferase activity and compared with cells with no siRNA. Results indicated that reduced expression of SEQ ID NO:5 led to retention of FOXO in the nucleus, similar to a reduced AKT effect. These results suggest involvement of MARK in the PTEN/IGF pathway.